See more : Tempo Automation Holdings, Inc. (TMPOW) Income Statement Analysis – Financial Results
Complete financial analysis of Black Diamond Therapeutics, Inc. (BDTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Black Diamond Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Integrated Wind Solutions ASA (IWS.OL) Income Statement Analysis – Financial Results
- Firma Holdings Corp. (FRMA) Income Statement Analysis – Financial Results
- SILICON RENTAL SOLUTIONS LIMIT (SRSOLTD.BO) Income Statement Analysis – Financial Results
- SpringWorks Therapeutics, Inc. (SWTX) Income Statement Analysis – Financial Results
- ADV.BLOCKCHAIN AG INH ON (ABX.DE) Income Statement Analysis – Financial Results
Black Diamond Therapeutics, Inc. (BDTX)
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 437.00K | 3.24M | 2.22M | 600.00K | 47.00K | 44.00K | 24.00K |
| Gross Profit | -437.00K | -3.24M | -2.22M | -600.00K | -47.00K | -44.00K | -24.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 59.35M | 64.44M | 96.83M | 48.21M | 21.75M | 6.95M | 3.45M |
| General & Administrative | 27.11M | 28.39M | 30.04M | 21.36M | 7.58M | 1.95M | 666.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.11M | 28.39M | 30.04M | 21.36M | 7.58M | 1.95M | 666.00K |
| Other Expenses | 0.00 | -354.00K | -2.19M | -1.72M | 6.00K | -16.00K | -6.00K |
| Operating Expenses | 86.46M | 92.83M | 126.87M | 69.57M | 29.33M | 8.90M | 4.12M |
| Cost & Expenses | 86.46M | 92.83M | 126.87M | 69.57M | 29.33M | 8.90M | 4.12M |
| Interest Income | 1.92M | 2.03M | 3.46M | 4.04M | 461.00K | 4.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 1.00K | 0.00 | 0.00 | 65.00K |
| Depreciation & Amortization | 437.00K | 3.24M | 2.22M | 600.00K | 47.00K | 44.00K | 24.00K |
| EBITDA | -86.02M | -92.32M | -126.67M | -66.65M | -29.29M | -8.89M | -4.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -86.46M | -92.83M | -126.87M | -69.57M | -8.90M | -8.90M | -4.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.02M | 1.66M | 1.28M | 2.32M | -5.93M | -27.00K | -483.00K |
| Income Before Tax | -82.44M | -88.92M | -125.60M | -67.25M | -35.26M | -8.93M | -4.60M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.40M | -2.39M | -1.78M | 5.89M | -27.00K | 59.00K |
| Net Income | -82.44M | -84.52M | -123.20M | -65.48M | -41.14M | -8.93M | -4.60M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.88 | -2.33 | -3.40 | -1.99 | -1.15 | -0.64 | -0.64 |
| EPS Diluted | -1.88 | -2.33 | -3.40 | -1.99 | -1.15 | -0.64 | -0.64 |
| Weighted Avg Shares Out | 43.95M | 36.33M | 36.19M | 32.91M | 35.91M | 13.95M | 7.20M |
| Weighted Avg Shares Out (Dil) | 43.95M | 36.33M | 36.19M | 32.91M | 35.91M | 13.95M | 7.20M |
Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Down 32.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference
Black Diamond Therapeutics to Present at the Jefferies Global Healthcare Conference
Black Diamond Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Executives Buy Around $1.6M Of 4 Penny Stocks
Black Diamond Therapeutics to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference
Source: https://incomestatements.info
Category: Stock Reports